Across TCGA pan-cancer cohorts, DEFB106B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB106B data layer compared with 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DEFB106B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB106B expression acts as an unfavorable survival marker.

SKCM are the cancer types where DEFB106B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.230	0.781	.004	22	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: DEFB106B tumor-vs-normal RNA expression · all DEFB106B data types